by Bogdan Lihanceanu | Dec 12, 2023
Moclobemide is a specific and reversible monoamine oxidase-A (MAO-A) inhibitor. Studies show that it is an effective and well-tolerated treatment for attention-deficit hyperactivity disorder (ADHD). A number of reports suggest that ADHD may have a causal influence on...
by Bogdan Lihanceanu | Dec 12, 2023
PURPOSE: Major depressive disorder (MDD) and alcohol dependence (AD) frequently occur together. However, MDD clinical trials generally exclude patients with alcohol-related disorders. GENERAL METHODS: A 12-week, open-label trial of nefazodone in a group of people...
by Bogdan Lihanceanu | Dec 12, 2023
Gabapentin is an antiepileptic drug shown to be effective in the treatment of pain disorders and appears to be useful as well for several psychiatric disorders, including bipolar disorder, anxiety disorders, alcohol withdrawal and cocaine dependence. Gabapentin, at a...
by Bogdan Lihanceanu | Dec 12, 2023
Symptoms of anxiety and depression are common in a large proportion of alcohol-abusing/dependent individuals during alcohol detoxification. The aim of this study was to examine the impact of a combined psychotherapeutic-psychopharmacological (either with mirtazapine...
by Bogdan Lihanceanu | May 15, 2009
Substance use disorder is the most common psychiatric comorbidity in schizophrenic patients, with prevalence rates of up to 65%. Recommendations for antipsychotic pharmacotherapy in schizophrenia are based on studies that excluded patients with this dual diagnosis. In...
